Car t-cell therapy for relapsed leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment using special immune cells (called CAR T cells) that are designed to find and destroy leukemia cells that carry a marker called CD7. It is for people whose T-cell or myeloid leukemia has returned or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 14 years old.
- You have a type of blood cancer called T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) or acute myeloid leukemia (AML).
- Your cancer has either come back after treatment or did not respond to standard therapy.
- Your cancer cells test positive for a protein called CD7.
- You are expected to live at least 3 more months.
- Your major organs (like heart, kidneys, liver, lungs) are working well enough, with no uncontrolled infections or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a lab-made immune cell treatment (CAR T-cells) aimed at T-cell leukemia that has come back or did not respond. It may help by targeting leukemia cells with a specific marker (CD7), especially in patients who failed standard treatment.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This study tests a new type of therapy called CAR T-cells for people with blood cancers that have returned or not responded to standard treatments. CAR T-cells are made from your own immune cells and are trained to find and kill cancer cells.
This trial tests a new immune therapy called CD7 CAR-T cells for people with acute leukemia that has come back or hasn't gotten better with standard treatments. It aims to see if this treatment is safe and can help control the leukemia.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial is studying whether a new kind of cellular therapy, called anti-CD7 CAR-T, can help people with relapsed or refractory T-cell lymphoma/leukemia by targeting a specific protein (CD7) on their cancer cells. The treatment uses your own immune cells that are reprogrammed to find and destroy the malignant cells.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.